604
Views
0
CrossRef citations to date
0
Altmetric
Editorial Comment

No ‘one size fits all’ approach in the management of high-risk non-muscle invasive bladder cancer

Page 53 | Received 14 Dec 2020, Accepted 16 Dec 2020, Published online: 11 Jan 2021

References

  • Wang E, Larrson U, Gardmark T, et.al. Radical cystectomy compared to intravesical BCG immunotherapy for high-risk non-muscle invasive bladder cancer – is there a long-term survival difference? – Submitted to the SJUN (SJUN-2020-0606).
  • Babjuk M, Burger M, Compérat EM, et al. European Association of Urology guidelines on non-muscle-invasive bladder cancer (TaT1 and carcinoma in situ) - 2019 update. Eur Urol. 2019;76(5):639–657.
  • Oughton JB, Poad H, Twiddy M, et al. Radical cystectomy (bladder removal) against intravesical BCG immunotherapy for high-risk non-muscle invasive bladder cancer (BRAVO): a protocol for a randomised controlled feasibility study. BMJ Open. 2017;7(8):e017913.

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.